Neuphoria Therapeutics (NEUP) closed at $3.05 on October 30, 2026, down 0.3% from the previous close, on volume of 61,600 shares (30-day average 21,156).
Data as of October 30, 2026.
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 4-Aug 4:40 PM ET)
Scancell’s Merger with Neuphoria Promises Expanded Nasdaq Presence and $89M in Fresh Financing
Market Chameleon (Thu, 23-Jul 6:29 AM ET)
Neuphoria Launches Strategic Review After Unsolicited Buyout Proposal and Director Nominations
Market Chameleon (Tue, 11-Nov 4:17 AM ET)
Market Chameleon (Wed, 12-Feb 3:37 AM ET)
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Neuphoria Therapeutics trades on the NASDAQ stock market under the symbol NEUP.
As of October 30, 2026, NEUP stock price declined to $3.05 with 61,600 million shares trading.
NEUP has a beta of -1.22, meaning it tends to be less sensitive to market movements. NEUP has a correlation of 0.01 to the broad based SPY ETF.
NEUP has a market cap of $16.50 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that NEUP belongs to (by Net Assets): PSIL, VTI, VXF.
NEUP has underperformed the market in the last year with a price return of -30.7% while the SPY ETF gained +12.3%. NEUP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.2% and -7.6%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
NEUP support price is $2.95 and resistance is $3.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEUP shares will trade within this expected range on the day.
